Your browser doesn't support javascript.
loading
Mesenchymal Stem Cells Therapies on Fibrotic Heart Diseases.
Gubert, Fernanda; da Silva, Jaqueline Soares; Vasques, Juliana F; de Jesus Gonçalves, Renata Guedes; Martins, Robertta Silva; de Sá, Mauro Paes Leme; Mendez-Otero, Rosalia; Zapata-Sudo, Gisele.
Afiliación
  • Gubert F; Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21944-590, Brazil.
  • da Silva JS; Programa Redes de Pesquisa em Saúde no Estado do Rio de Janeiro, Rio de Janeiro 21944-590, Brazil.
  • Vasques JF; Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21944-590, Brazil.
  • de Jesus Gonçalves RG; Programa Redes de Pesquisa em Saúde no Estado do Rio de Janeiro, Rio de Janeiro 21944-590, Brazil.
  • Martins RS; Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21944-590, Brazil.
  • de Sá MPL; Programa Redes de Pesquisa em Saúde no Estado do Rio de Janeiro, Rio de Janeiro 21944-590, Brazil.
  • Mendez-Otero R; Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21944-590, Brazil.
  • Zapata-Sudo G; Programa Redes de Pesquisa em Saúde no Estado do Rio de Janeiro, Rio de Janeiro 21944-590, Brazil.
Int J Mol Sci ; 22(14)2021 Jul 12.
Article en En | MEDLINE | ID: mdl-34299066
Stem cell therapy is a promising alternative approach to heart diseases. The most prevalent source of multipotent stem cells, usually called somatic or adult stem cells (mesenchymal stromal/stem cells, MSCs) used in clinical trials is bone marrow (BM-MSCs), adipose tissue (AT-MSCs), umbilical cord (UC-MSCs) and placenta. Therapeutic use of MSCs in cardiovascular diseases is based on the benefits in reducing cardiac fibrosis and inflammation that compose the cardiac remodeling responsible for the maintenance of normal function, something which may end up causing progressive and irreversible dysfunction. Many factors lead to cardiac fibrosis and failure, and an effective therapy is lacking to reverse or attenuate this condition. Different approaches have been shown to be promising in surpassing the poor survival of transplanted cells in cardiac tissue to provide cardioprotection and prevent cardiac remodeling. This review includes the description of pre-clinical and clinical investigation of the therapeutic potential of MSCs in improving ventricular dysfunction consequent to diverse cardiac diseases.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrosis / Trasplante de Células Madre Mesenquimatosas / Células Madre Mesenquimatosas / Cardiopatías Límite: Animals / Humans Idioma: En Revista: Int J Mol Sci Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrosis / Trasplante de Células Madre Mesenquimatosas / Células Madre Mesenquimatosas / Cardiopatías Límite: Animals / Humans Idioma: En Revista: Int J Mol Sci Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Suiza